Jacobio Pharmaceuticals Group Co., Ltd. (1167.HK)
| Previous close | 1.620 |
| Open | 1.620 |
| Bid | 1.630 x N/A |
| Ask | 1.640 x N/A |
| Day's range | 1.600 - 1.660 |
| 52-week range | 1.380 - 6.480 |
| Volume | |
| Avg. volume | 1,238,989 |
| Market cap | 1.289B |
| Beta (5Y monthly) | 0.54 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.500 |
| Earnings date | 28 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.28 |
PR NewswireJacobio Pharma Presents SHP2 Plus KRAS G12C Data at ASCO
Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, presented updated data of a KRAS G12C inhibitor glecirasib (JAB-21822) in combination with a SHP2 inhibitor (JAB-3312) in frontline non-small cell lung cancer (NSCLC) patients harboring KRAS G12C mutation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting as form of oral presentation. Jacobio also presented updated data of pivotal phase II study of glecirasib as form of oral presenta
PR NewswireJacobio Pharma Announced its KRAS G12C inhibitor reached the primary endpoint
Jacobio Pharma (1167.HK) announced that the data from the Phase II registrational study of the KRAS G12C inhibitor glecirasib were offically reported at the April ASCO Plenary Series, which was held online.
PR NewswireJacobio Pharma to Present Data of PARP7 Inhibitor and P53 Reactivator at the 2024 AACR Annual Meeting
Jacobin Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, today announced that the company will present the results of two preclinical evaluation of PARP7 inhibitor JAB-26766 and p53 Y220C reactivator JAB-30355 in form of the abstract during the American Association for Cancer Research (AACR) Annual Meeting 2024 (the "AACR 2024") from April 5 to 10, 2024.
